جستجوی استاد راهنمای دانشگاهی

Laura Solt, Ph.D. is an Associate Professor in the Department of Immunology and Microbiology at the Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology in Jupiter, Florida. She also serves as Associate Dean of the Skaggs Graduate School of Chemical and Biological Sciences. Dr. Solt began her independent research career at Scripps Florida in 2013 and has established herself as a leading researcher in nuclear receptor biology within the immune system. Her research focuses on understanding the biologically relevant roles of nuclear receptors, particularly RORα and REV-ERBs, in the immune system with emphasis on TH17 cell development and autoimmune disease. Her lab employs a multidisciplinary approach combining molecular biology, genetic techniques, and chemical biology coupled with mouse models of autoimmunity and chronic inflammation. Dr. Solt's laboratory has made significant contributions to understanding how nuclear receptors regulate immune cell function, particularly in TH17-mediated inflammation. Her work has demonstrated roles for RORα and REV-ERBs in TH17 cell development and has developed synthetic ligands to these receptors for potential therapeutic applications in autoimmune diseases. Her extensive publication record shows a clear trajectory of research focused on nuclear receptor signaling in immunity, with recent work expanding into applications for cancer immunotherapy, neuroimmunology, and metabolic aspects of immune cell function. Her articles demonstrate expertise in both basic nuclear receptor mechanisms and translational applications. Ruth L. Kirschstein National Research Service Awards (2010-2013) Dr. Solt actively mentors graduate students including Adrianna Wilson (recipient of NIDDK F31 and Scheller Graduate Student Fellowship) and Sarah Mosure (recipient of NIH NRSA F31 award and Wendy Havran award). Her laboratory receives substantial funding from multiple NIH institutes (NIDDK, NCI, NIAID, NIGMS) as well as the Crohn's & Colitis Foundation. Current research directions include investigating the roles of NR2F6 in TH17 cells, exploring RORα function in CD8 T cells, and developing novel nuclear receptor modulators for therapeutic applications.

• Autoimmune Disease
• Cancer Immunotherapy
• Immunometabolism
• +۵ مورد دیگر

Gustavo Nader, Ph.D., is a Professor of Kinesiology at The Pennsylvania State University's College of Health and Human Development, where he holds the Dorothy Foehr Huck and J. Loyd Huck Endowed Chair in Molecular, Cellular and Integrative Physiology. His research laboratory at 101 Noll Lab focuses on molecular mechanisms of skeletal muscle adaptation, employing human, animal, and cellular models to investigate ribosome biogenesis, transcriptional regulation, and muscle growth control in contexts ranging from exercise hypertrophy to cancer cachexia. Dr. Nader's research examines fundamental processes including: Ribosome biogenesis and its role in muscle growth regulation Epigenetic control of RNA Polymerase I activity Molecular pathways in mechanical overload-induced hypertrophy Tumor-induced muscle wasting mechanisms Biomimicry approaches inspired by hibernator physiology His work spans exercise physiology, cancer biology, and environmental stress responses. Analysis of his 15 most recent publications (2015-2025) reveals predominant themes in muscle hypertrophy mechanisms, cancer cachexia pathophysiology, ribosomal function analysis, and environmental stress impacts on muscle. His work consistently integrates molecular techniques with physiological models across species. Notable scientific recognitions include: Dorothy Foehr Huck and J. Loyd Huck Chair appointment (2024) Huck Institutes Leadership Fellowship (2025-2026) Dr. Nader leads an active research team investigating muscle plasticity, with current projects funded through the Huck Institutes of the Life Sciences. He collaborates extensively through Penn State's Integrative and Biomedical Physiology graduate program and Center for Cellular Dynamics.

• Skeletal Muscle Growth
• Ribosome Biogenesis
• Exercise Physiology
• +۴ مورد دیگر

Yeonhwa Park is a Professor and holder of the Francis Chair in the Department of Food Science at the University of Massachusetts Amherst. Her research focuses on functional foods, bioactive components, and environmental contaminants' effects on obesity and aging. She investigates food bioactives like conjugated linoleic acid (CLA) and environmental pollutants like PFAS to understand their roles in metabolic disorders and aging mechanisms. Her work spans multiple models, including C. elegans, zebrafish, and rodent studies, emphasizing translational applications for human health. Teaching responsibilities include courses such as 'Science of Food' (FS150), 'Biology of Food in Human Health' (FS270), and 'Bioactive Food Components' (FS750). Awards include Clarivate Highly Cited Researcher (2017–2018), Faculty Convocation Award (2015), and the Timothy Mounts Award (2015). Her research has been published in over 150 peer-reviewed articles, with recent emphasis on environmental contaminants' impact on obesity and type 2 diabetes, and the use of C. elegans for screening bioactives. Key findings include CLA's role in fat reduction, PFAS-induced metabolic disruption, and the application of alternative models (e.g., C. elegans) to reduce animal testing. Her lab integrates molecular biology, toxicology, and food science to address global health challenges like the obesity epidemic and environmental toxin exposure.

• Functional Foods
• Obesity
• Environmental Contaminants
• +۳ مورد دیگر

Dr. Ling Zhu is an Associate Professor and Senior Research Fellow at the Save Sight Institute, University of Sydney. He holds dual affiliations with the Centre for Drug Discovery Innovation and the University of Sydney Nano Institute. His research focuses on retinal diseases, including diabetic retinopathy, age-related macular degeneration, and macular telangiectasia type 2, combining clinical and basic research approaches. Dr. Zhu leads a lab with a postdoc, two research assistants, and one HDR student, emphasizing innovative techniques like human retinal explant culture and nanomedicine. Dr. Zhu obtained his PhD in Biochemistry from Rutgers University (USA) in 2008. His work has attracted over $2 million in research funding in the past five years and includes 93 publications (3590 citations, H-index 34). He is a major author in leading journals like eLife and Ophthalmology . Current research projects include preclinical RNA-LNP therapy for retinal degeneration, targeting retinal metabolism for macular diseases, and developing a 'Macula-on-a-Chip' drug screening platform. His expertise spans biochemistry, molecular biology, and translational nanomedicine. Key achievements include establishing human retinal explant models and advancing lipid nanoparticle-based drug delivery systems. Dr. Zhu collaborates widely, with projects addressing unmet clinical needs in ophthalmology and drug discovery.

• Ophthalmology
• Retinal Degeneration
• Nanomedicine
• +۳ مورد دیگر

Océane Martin is a Lecturer in Clinical Microbiology at the University of Bordeaux, where she conducts her research at the Institute of Cellular Biochemistry and Genetics, a joint unit of CNRS and the university. Her work bridges clinical microbiology, oncology, and nutritional sciences. Research Interests: Océane Martin specializes in the role of the microbiota in cancer development, particularly focusing on: Links between processed meat consumption, nitrites/nitrates, and colorectal cancer. The role of pathogenic bacteria like Helicobacter pylori and Salmonella in gastric and colorectal cancers. The gut-brain axis in glioblastoma, including how the microbiota influences tumor progression and therapeutic resistance through the GLIOBIOTA project. Intratumoral microbiota in brain tumors and their functional implications. Publication Trends: Her recent publications reflect a strong focus on bacterial genotoxins, DNA damage responses, host immune modulation, and dietary factors in carcinogenesis. Her work integrates molecular microbiology with immunology and cancer biology, often using in vivo models to study host-pathogen dynamics. Scientific Contributions: Member of ANSES working group (2020–2022) on nitrite salts in food. Invited expert at the French National Assembly on nitrite-related health risks. Regular contributor to public science communication via The Conversation and national media. Advising and Grants: While no formal students are listed, her leadership in the GLIOBIOTA project suggests active mentorship and grant-funded research. Her involvement in national expert panels and interdisciplinary projects indicates sustained funding and collaborative research networks. Labs and Teams: She conducts research at the Institute of Cellular Biochemistry and Genetics (University of Bordeaux / CNRS), contributing to teams focused on infection biology, microbiota, and cancer. Her work aligns with translational research initiatives linking diet, microbiology, and oncology.

• Microbiota
• Cancer Biology
• Clinical Microbiology
• +۹ مورد دیگر

Simon Arthur is a Professor of Immune Signalling at the University of Dundee, School of Life Sciences, within the Department of Cell Signalling and Immunology. His research focuses on understanding inflammatory processes, particularly the role of innate immune cells in coordinating inflammation and resolving immune responses. He holds a PhD from the University of Oxford (1995) and a BSc from Durham University (1990). Arthur is a Fellow of the Royal Society of Biology (2015) and serves on the editorial board of the Journal of Biological Chemistry . His teaching includes courses on Genetics, Cell Signalling, Immunology, and advanced topics in immunology and cell signalling. He supervises PhD projects on microglial phenotypes in brain ageing and immunomodulatory factors in helminth-host interactions. Arthur leads research projects funded by the Medical Research Council and other agencies, including studies on liver fibrosis, bile acid diarrhoea, and pulmonary fibrosis. Key research themes include cytokine regulation, macrophage function, and the molecular mechanisms underlying chronic inflammation. His work spans from fundamental biology to translational research, aiming to develop therapies for autoimmune and inflammatory diseases. Arthur collaborates internationally and has over 180 publications in high-impact journals.

• Immunology
• Cell Signalling
• Inflammation Biology
• +۳ مورد دیگر

Eduardo N. Chini, M.D., Ph.D., is a Professor at Mayo Clinic with primary and joint appointments in the Department of Anesthesiology and Perioperative Medicine and the Department of Cancer Biology. He is based in Rochester, Minnesota, and leads a research program focused on NAD metabolism, aging, and their roles in diseases such as cancer, obesity, and kidney disease. Education: BS in Biology, Centro Educacional de Niteroi-RJ MD, Universidade do Rio de Janeiro PhD in Biological Chemistry, Universidade do Rio de Janeiro Fellow, Department of Physiology and Biophysics, Mayo Clinic Resident in Anesthesiology, Mayo Clinic College of Medicine Research Interests: Eduardo N. Chini's research investigates the central role of nicotinamide adenine dinucleotide (NAD) in cellular metabolism, aging, and disease. His lab has made foundational discoveries in NAD catabolism, identifying CD38 as the primary enzyme regulating NAD levels in mammals. His work explores SIRT1 regulation via CD38 and DBC1, NAD metabolism in cancer, and its implications in polycystic kidney disease. He is particularly interested in how NAD signaling influences aging, metabolic syndrome, and organ dysfunction. Recent Research Trends: His recent publications (2023–2025) reveal a strong focus on the role of CD38 in aging, immune function, and tissue metabolism. Key themes include NAD+ depletion triggering inflammatory responses, CD38 inhibition as a therapeutic strategy for cardiotoxicity and metabolic aging, and the interplay between senescence, stem cell function, and mitochondrial health. His work increasingly integrates translational models with molecular mechanisms in aging and cancer. Scientific Awards: Florida Investigator of the Year, Mayo Clinic (2024) Glenn/AFAR Breakthroughs in Gerontology Award (2007) Edward C. Kendall Award, Mayo Clinic Alumni Association (2002) Directors Award for Aging Research, Kogod Center on Aging (2018) Distinguished Scientist Seminar Series, Georgetown Medical School (2022) Grants and Leadership: Dr. Chini is a co-Principal Investigator on multiple NIH-funded grants, including projects on CD38 in scleroderma, CLL, and male reproductive aging. He is Co-Director of the Mayo Clinic Mitochondrial Care Center and Associate Director of the Robert and Arlene Kogod Center on Aging. He has served on numerous national review panels and advisory councils, including the NIH Hepatobiliary Pathophysiology Study Section and AFAR's National Scientific Advisory Council. Labs and Teams: Dr. Chini leads a research laboratory at Mayo Clinic focused on NAD metabolism and aging. His team collaborates extensively with experts in cancer biology, mitochondrial medicine, and aging research. He is affiliated with the Mayo Clinic Comprehensive Cancer Center, the Kogod Center on Aging, and the Robert M. and Billie Kelley Pirnie Translational PKD Center.

• Metabolism
• NAD Metabolism
• Aging
• +۱۱ مورد دیگر

Gustavo Alberto Nader is a Professor of Kinesiology at The Pennsylvania State University , holding the Dorothy Foher and J. Lloyd Huck Chair in Molecular, Cellular and Integrative Physiology. His research focuses on skeletal muscle growth control , ribosome biogenesis , and transcriptional/epigenetic regulation in health and disease contexts. Affiliated with the Huck Institutes of the Life Sciences and College of Health and Human Development Principal Investigator on NIH-funded projects examining ribosomal control of muscle mass Research Interests span molecular mechanisms of muscle adaptation to exercise, cancer cachexia, chronic disease impacts on muscle, and cross-species Wnt signaling regulation by CO₂ levels. Key methodologies include human/animal/cell models, ribosomal analysis, and epigenetic profiling. Publication Trends show sustained focus on: Ribosome biogenesis in muscle hypertrophy (2012–2025) Cancer-induced muscle wasting mechanisms (2015–2024) CO₂/Wnt pathway interactions (2015–2019) Exercise-induced transcriptional responses (2001–2016) Scientific Awards include the Huck Chair, while his Grants & Collaborations involve NIH-funded studies on transcriptional/epigenetic mechanisms (2019–2026) with cross-disciplinary teams in physiology, oncology, and respiratory medicine.

• Skeletal Muscle Physiology
• Ribosome Biogenesis
• Transcriptional Regulation
• +۴ مورد دیگر

Adrian Whitty is an Associate Professor in the Department of Biology at Boston University . His research focuses on protein-protein and protein-ligand recognition, particularly in developing mechanistic understandings of growth factor receptor activation and advancing drug discovery for protein-protein interaction inhibition. Education: B.Sc. (Honors) in Chemistry from King’s College, University of London (1985); Ph.D. in Organic Chemistry from the University of Illinois at Chicago (1991); Postdoctoral Research Fellow at Brandeis University's Biochemistry Department (1990-93). His work integrates biochemical and cell-based assays using advanced technologies like FRET, Time-Resolved Fluorescence, and Surface Plasmon Resonance (Biacore 3000). He collaborates with computational chemists, organic synthesis experts, X-ray crystallographers, and biologists to develop novel approaches for designing small molecule inhibitors of protein-protein interactions. Recent publications highlight trends in machine learning applications for molecular scientists, structural analysis of enzyme mechanisms, macrocycle-based drug design, and quantitative studies of protein interaction energetics. His lab emphasizes rigorous hypothesis-driven experimental design, preparing students for careers in academia or industry. Advisory and leadership roles include membership in The Protein Society (2008-present), the American Society of Biochemistry and Molecular Biology (ASBMB) Governing Council (2007-present), and founding roles in the Council for Systems Biology in Boston (CSB2) and the Institute for Chemical Biology and Drug Discovery at SUNY Stony Brook. His laboratory is equipped with state-of-the-art facilities for fluorescence, analytical ultracentrifugation (AUC), dynamic light scattering (DLS), isothermal titration calorimetry (ITC), and tissue culture, supporting diverse techniques including flow cytometry and reaction pathway modeling with Mathematica and MATLAB.

• Biochemistry
• Structural Biology
• Drug Discovery
• +۳ مورد دیگر

Peter Schultz, PhD, is the President and CEO of Scripps Research, holding the L.S. “Sam” Skaggs Presidential Chair in the Department of Chemistry. He has been a faculty member since 1999, previously at UC Berkeley. His research spans synthetic biology, genetic code expansion, and drug discovery, with a focus on engineering organisms and molecules for biological and medical applications. Education: Ph.D. in Chemistry, California Institute of Technology (1984) B.S. in Chemistry, California Institute of Technology (1979) Research Interests: Expanding genetic codes to incorporate noncanonical amino acids in organisms Engineering endosymbiotic systems to study mitochondrial evolution Developing small molecules for cancer, stem cell therapies, and neglected diseases Designing antibodies and CAR-T cells for targeted therapies Article Trends: Recent work emphasizes small molecule therapies for cancer and fibrosis, synthetic biology applications in endosymbiosis, and genetic code expansion for protein engineering. Key themes include drug repurposing, targeted drug delivery, and molecular mechanisms of biological systems. Awards: Wolf Prize in Chemistry (1994) National Academy of Sciences Member (1993) Paul Ehrlich-and Ludwig Darmstaedter Prize (2002) National Academy of Inventors Fellow (2015) Advising & Grants: Supervises ~15 graduate students and postdocs annually. Secured funding from NSF, NIH, and industry partnerships. Over 85 former students hold academic positions globally. Labs/Teams: Heads the Schultz Lab at the Chi-Huey Wong Laboratories, focusing on biologically inspired synthesis and translational research.

• Biological Chemistry
• Genetic Code Expansion
• Stem Cell Biology
• +۳ مورد دیگر

Kathleen Mulvaney is an Assistant Professor at the Fralin Biomedical Research Institute at Virginia Tech and in the Department of Biomedical Sciences and Pathobiology at the Virginia-Maryland College of Veterinary Medicine. Her laboratory is located at the Children's National Research & Innovation Campus in Washington, D.C., where she leads research efforts focused on cancer biology and therapeutic development. Dr. Mulvaney's educational background includes: Ph.D. in Cell Biology from the University of North Carolina, Chapel Hill B.S. in Biology from the University of Rochester Dr. Mulvaney's research program centers on understanding and disrupting protein-protein interactions and protein modifications in cancer, with particular focus on pancreatic cancer and pediatric and adult brain cancers. Her laboratory investigates tumor dependencies - the specific enzymes and pathways that cancers rely on for survival - with the goal of translating these findings into meaningful clinical improvements for patient care. A significant portion of her recent work has focused on PRMT5, an enzyme found in approximately 15% of human cancers, exploring how to target this enzyme for therapeutic benefit. Her research employs CRISPR gene editing, molecular biology techniques, and biochemical approaches to identify vulnerabilities in cancer cells. Her laboratory has made significant contributions to understanding the molecular basis of substrate recruitment to the PRMT5 methylosome and has discovered first-in-class inhibitors of the PRMT5-substrate adaptor interaction. Recent work published in Cancer Research demonstrates a promising combination therapy approach for hard-to-treat cancers that lack specific tumor suppressor genes. These cancers, which include certain lung, brain, and pancreatic tumors, become dependent on PRMT5 for survival, making it a potential therapeutic target. Dr. Mulvaney has received numerous scientific awards and honors, including: National Institutes of Health F32 Ruth L. Kirschstein Postdoctoral Individual National Research Service Award (2018-2021) National Institutes of Health LRP Award (2019-2021) Sigma Xi Research Society Graduate Student Travel Award (2015) National Science Foundation Graduate Research Fellowship Honorable Mention (2011, 2012) Dr. Mulvaney actively mentors graduate students and postdoctoral researchers in her laboratory at the Children's National Research & Innovation Campus. Her research is supported by grants from the National Institutes of Health, including an R35 grant to examine cancer-related enzymes. She collaborates extensively with researchers across Virginia Tech and Children's National Hospital to advance cancer research and therapeutic development, participating in the Virginia Tech Cancer Research Alliance which brings together scientists and physicians to develop innovative approaches to cancer treatment. The Mulvaney Lab is part of the Cancer Research Center - D.C. at the Children's National Research & Innovation Campus, where they work alongside other researchers in the Children's Cancer and Immunobiology Center. This collaborative environment allows for interdisciplinary approaches to understanding cancer biology and developing novel therapeutic strategies, with particular emphasis on translating basic science discoveries into clinical applications for hard-to-treat cancers.

• Cancer Biology
• Protein-Protein Interactions
• Cancer Therapeutics
• +۷ مورد دیگر

Karl Hemming is a Senior Lecturer in Organic Chemistry at the University of Huddersfield , affiliated with the School of Applied Sciences and the Department of Physical and Life Sciences . He is a member of the Chemical Synthesis and Design Centre , with associate memberships in the Pharmacology and Therapeutics Centre and Microbial Therapeutics and Infection Control Centre . PhD supervision available External Examiner at University of Greenwich (2021–) Royal Society of Chemistry accreditation roles Research Focus: Synthesis of heterocyclic compounds (cyclopropenones, pyrrolobenzodiazepines, isoflavones) for pharmaceutical applications, emphasizing anti-inflammatory and neuroprotective properties. His work bridges organic synthesis, medicinal chemistry, and drug delivery systems. Publication Trends: 1992–2021 output spans Cycloaddition Reactions , Nitrogen Heterocycles , and Anti-inflammatory Agents , with recent emphasis on hybrid molecules combining isoflavones with benzodiazepines or sultams. Methodologies include 1,3-cycloadditions, aza-Wittig reactions, and multicomponent synthesis. External Roles: Actively involved in academic validation (Royal Society of Chemistry), peer-review for Organic Letters and Journal of Organic Chemistry , and local chemistry community leadership (Chair of Royal Society of Chemistry Huddersfield Local Section Committee).

• Organic Chemistry
• Synthetic Organic Chemistry
• Heterocyclic Compounds
• +۳ مورد دیگر

Benjamin G. Keselowsky is a Professor in the J. Crayton Pruitt Family Department of Biomedical Engineering at the University of Florida's Herbert Wertheim College of Engineering. His research focuses on engineering biomaterial-immune cell interactions and controlled release systems for immunotherapies, with applications in implanted devices, vaccines, and tissue engineering. He holds a B.S. in Chemical Engineering (University of South Florida, 1998) and a Ph.D. in Bioengineering (Georgia Institute of Technology, 2004). Key honors include AIMBE Fellowship (2018), UF Preeminence Term Professorship (2017-2020), and UF Research Foundation Professorship (2015-2018). His work bridges biomaterials science and immunology, emphasizing translational strategies for immune modulation. Recent efforts include developing bioresorbable alloys, enzyme-delivery systems, and antigen-specific microparticle therapies. Education: B.S., Chemical Engineering, University of South Florida (1998); Ph.D., Bioengineering, Georgia Tech (2004) Research Themes: Biomaterial-Immune System Interactions Controlled Release of Immune Modulators Tissue Engineering and Regenerative Medicine Awards: AIMBE Fellow (2018) UF Preeminence Term Professor (2017-2020) UF Research Foundation Professor (2015-2018) His lab's innovations include microparticle systems for treating autoimmune diseases and enzymatic gels for localized therapy. Collaborations span biomaterials design, immunotherapy development, and clinical translation.

• Biomaterials Engineering
• Immunotherapy
• Controlled Release Systems
• +۳ مورد دیگر

Emily Hobson is a Lecturer in Pharmacology at the School of Chemistry, Pharmacy and Pharmacology, University of East Anglia (UEA), where she also earned her BSc in Pharmacology and Drug Discovery in 2019. She completed her PhD in cancer biology at UEA's School of Pharmacy, focusing on the transcription factor Nrf2 in lung and melanoma cancers. She has held prior teaching positions as Lecturer in Cell Biology and Immunology at UEA before moving to her current role in 2024. Education: Bachelor of Science in Pharmacology and Drug Discovery, University of East Anglia (2019) Her primary research interests lie in cancer biology and inflammation , with a focus on identifying and validating novel drug targets and understanding dysregulated signaling pathways in cancer. She is also actively involved in pedagogical research , having achieved Fellowship of the Higher Education Academy in 2024, reflecting her commitment to teaching excellence. While no publications are listed in the provided text, her work appears to bridge translational pharmacology and cancer therapeutics, as evidenced by her research project on cancer medicines development. Her professional engagement suggests a strong interdisciplinary and educational focus. Scientific and Professional Affiliations: Chair, Early Career Pharmacologists Advisory Group (ECPAG), British Pharmacological Society (2022–2024) Member, Early Career Pharmacologists Advisory Group (ECPAG), British Pharmacological Society (2022–present) Early Career Representative, Norwich Cancer Research Network (2020–present) Emily serves as the Outreach and Engagement Officer for her School and is the module organiser for PHAP6015B. She led a research project funded by the British Pharmacological Society titled Cancer medicines: From the laboratory to the patient (Jan–Feb 2023), indicating active engagement in both research and public communication of science. She is involved in team-based cancer research networks and contributes to institutional and national initiatives supporting early-career pharmacologists. Her future work is likely to expand on targeted cancer therapies and innovative teaching methods in pharmacology.

• Cancer Biology
• Inflammation
• Pharmacology
• +۴ مورد دیگر

Vidya Chandrasekaran is a Researcher at the Vrije Universiteit Amsterdam, affiliated with the Faculty of Science and the Department of Chemistry and Pharmaceutical Sciences. She holds an integrated Master's degree in Industrial Biotechnology from SASTRA University, India (2015), and is completing a PhD focused on iPSC-derived renal proximal tubule models for nephrotoxicity testing. Her research emphasizes developing in vitro systems for toxicity assessment using induced pluripotent stem cells (iPSCs). Key research areas include: iPSC differentiation protocols for kidney cells Nephrotoxicity testing using organoid models Transcriptomic analysis of toxic responses Animal-free chemical safety assessment She contributed to the in3 project , a multidisciplinary initiative for animal-free toxicity testing, alongside Prof. Paul Jennings. Her work has been published in journals like Toxicology in Vitro and Scientific Reports . Current projects involve advancing chronic toxicity prediction models and cadmium exposure mechanisms in renal cells. Collaborations include Harvard Medical School and Brigham and Women’s Hospital, focusing on kidney toxicology and regenerative medicine.

• Toxicology
• In Vitro Toxicology
• Stem Cell Research
• +۴ مورد دیگر